120 results about "Viral contamination" patented technology

Combinations of silver and copper ion sources or a single source of both silver and copper ions are found effective in methods for treating viral infections and for treating surfaces so as to eradicate viral contaminants and/or prevent subsequent contamination of said surfaces with viruses. These methods are particularly applicable in addressing SARS and avian flu viruses.

The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m². Further, the invention relates to the use of a preparation, being a cell culture medium or at least a component of a cell culture medium obtainable according to method of the invention for cell culture; pharmaceutical, diagnostic and/or cosmetic preparations as well as in food preparations.

Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0˜6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native.

The present invention provides a process for producing virus-like particles, which can produce virus-like particles having the protein of a virus and a lipid bilayer membrane derived from an eukaryotic microorganism as an outer membrane in a short period of time in a form that is not contaminated with a vector virus, and which enables the virus-like particles to be used for various applications. The process of the present invention comprises: (a) incorporating a gene encoding a protein essential for viral particle budding or a fragment thereof into a vector which can be expressed in a eukaryotic microorganism; (b) transfecting the vector into the eukaryotic microorganism; (c) culturing a transformed eukaryotic microorganism; (d) removing a cell wall of the eukaryotic microorganism; and (e) further culturing, followed by collection of a culture supernatant.

The invention relates to a serum-free protein-free high-efficiency feed culture medium as well as a preparation method and application thereof. The feed culture medium comprises amino acids, inorganic salts, trace elements, vitamins, carbohydrates and other organic matters. Moreover, the culture medium does not contain any glutamine. Since the feed culture medium contains serum-free protein-free animal-source-free components, the viral pollution risk can be greatly reduced, and downstream purification is facilitated. Meanwhile, since the culture medium is full in types of formula components and balanced in proportion, the culture medium can be applicable to high-density culture and high-protein expression of multiple CHO cell strains.

Herein is described a new method for partition and inactivating of viral and prion contaminants contained in a solution. The method is based on ultracentrifugation of the solution in a centrifuge tube at the bottom of which a high molarity urea solution is layered. The system can include a cushion solution interposed as an intermediate liquid phase between the starting solution and the urea solution.

The invention relates to the technical field of biomedicine, in particular to cell cryopreservation fluid and application thereof. The cell cryopreservation fluid disclosed by the invention is prepared from the following components: dimethyl sulfoxide, human albumin, low-molecular dextran, a human mesenchymal stem cell exosome, hydroxyethyl starch and a basal culture medium. Cells cryopreserved and revived by using the cell cryopreservation fluid are high in viability, the morphologic change is not large, differentiation cannot be caused during culture, and surface antigen detection accords with the standard; in addition, by optimizing a cell cryopreservation scheme, death of a large amount of cells caused by ice crystal formation during a cryopreservation process of the cells can be avoided as much as possible, a cryopreservation system is optimized, revived cells can be directly fed back to a human body, and animal derived serum is not added, animal derived virus infection is avoided; the cell cryopreservation fluid is wide in application, and the technical problem that the cell viability after the reviving of the cells which are cryopreserved by an existing cell cryopreservationsystem is not high is solved.

Methods, cells and recombinant adenoviral vectors are disclosed that permit the production of recombinant adenoviral vector stocks with reduced levels of contamination by replication competent adenoviruses (RCA). In certain embodiments are disclosed early region 1 (E1) deficient recombinant adenoviral vectors and complementing E1 positive host cells whose sequences are designed to avoid formation of RCA by homologous recombination between sequences in the vector and E1 sequences in the cells. One aspect of the invention involves the inversion of the packaging signal in a recombinant adenoviral vector relative to an adjacent or nearby inverted terminal repeat (ITR). Methods include use of site-specific intregrase family recombinases such as Cre or FLP and recombinase recognition sites such as lox sites or frt sites.

The present invention relates to methods and processes of inactivating viral contaminants in a biological source material (e.g. a host cell, cell supernatant, cell lysate, blood plasma, tissue homogenate, or other biological materials) with a solution containing one or more alkylamine compounds. In a particular embodiment, the active ingredients are amphipathic, charged amines or amine oxides coupled to saturated hydrocarbon chains of varying lengths.

The invention discloses a method for preparing a serum-free soybean protein peptide animal cell medium, and relates to a serum-free or low-serum collective cell medium. The serum-free soybean protein peptide animal cell medium is prepared from calcium chloride, potassium chloride, anhydrous magnesium sulfate, sodium chloride, anhydrous sodium dihydrogen phosphate, L-glutamine, D-glucose, phenol red, D-calcium pantothenate, choline chloride, folic acid, i-inositol, niacinamide, pyridoxal hydrochloride, lactoflavin, thiamine hydrochloride, soybean protein peptide and distilled water. The method of the invention solves the problem that the conventional serum-free medium cannot be directly used for cultivating cells in the poor growth condition, and a large number of the cells can adapt to the conventional serum-free medium only when the serum concentrations thereof are gradually reduced, and the cells are easily affected by external factors, so fatal damages are easily caused. The method of the invention has the advantages that the cells can directly be cultivated in the medium of the invention without gradual domestication and cultivation, so the culture period of the cell is shortened and the interference of other factors is avoided; meanwhile, the virus pollution brought by serums is reduced, and the survival rate of the cells is over 94 percent.

The invention discloses a method for replicating and proliferating avian influenza viruses in the passage cells which are absorbed and grow in the microcarrier of a bioreactor. The invention is based on the method which uses cells as carrier to proliferate viruses in the bioreactor. The obtained avian influenza viruses and the avian influenza virus vaccine product have uniform quality and stable toxicity. The automatic control of vaccine production can be realized, the problem of large-scale production and application can be solved, the production matrix of the influenza vaccine can be completely changed, the technology that chick embryo is adopted to culture viruses can be changed, the problems caused by chick embryo such as adventitious agent pollution and viral pollution and the interferences caused by heterologous proteins such as chick embryo can be reduced, the purity, safety and immune effect of vaccine can be increased and the method can play an important role in the prevention of avian influenza.

There is provided a smart face protective device, preferably as part of a helmet or another head held device, to be used by a user for preventing or reducing spread of infectious droplets through a portal portion of the user's face, where the face protective device is configured to be automatically adjusted while being in use between a secured position and an unsecured position based on an electric signal associated to a monitored health and safety condition of the user. There is also provided a system, a network and a method for allocating smart face protective devices to members of a community and managing these devices and data collected thereby for preventing or reducing risks of virus contamination and spread, namely COVID-19, between the members of the community.

Contaminant viruses can be efficiently removed almost without losing the activity of protein by subjecting a plasma protein composition having a high risk of viral contamination to a treatment with a porous membrane having a pore size greater than a single-particle size of the virus, particularly by subjecting a plasma protein composition to a fractionation treatment by precipitation, before the porous membrane treatment. Particularly, a fibrinogen composition substantially free of non-enveloped viruses, Parvovirus among others, can be provided. By the application of the present invention, a safe plasma protein preparation free of viruses can be conveniently provided.

A support platform for wall mounted toilets is described. The platform attaches easily under the toilet and contains bolts and feet for adjustment. The platform provides support to wall mounted toilets so that persons of weight greater than the rated load of the wall mounted toilet can use the toilet in comfort and safety. It is removable for use in different bathrooms, easily transported and can be sterilized where bacterial or viral contamination is a concern.